Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracheobronchial Stenosis in Granulomatosis With Polyangiitis: Immunosuppressant Use and Airway Dilation Frequency.

ACR open rheumatology·2026
Same author

Pulmonary manifestations of granulomatosis with polyangiitis and microscopic polyangiitis.

Seminars in arthritis and rheumatism·2026
Same author

Infracordal Stenosis: A Glucocorticoid-Responsive Subtype of Autoimmune Laryngotracheal Stenosis.

The Laryngoscope·2026
Same author

Subcordal Stenosis: A Glucocorticoid-Responsive Subtype of Autoimmune Laryngeal Stenosis.

medRxiv : the preprint server for health sciences·2025
Same author

Tracheobronchial Stenosis in Granulomatosis with Polyangiitis: Immunosuppressant Use and Airway Dilation Frequency.

medRxiv : the preprint server for health sciences·2025
Same author

Large Language Models Are Not Role Models: A Meditation on Master Clinicians.

The American journal of medicine·2025
Same journal

Chronic recurrent multifocal osteomyelitis-case report of two patients and review of literature.

International journal of clinical rheumatology·2019
Same journal

Association of weight loss with improved disease activity in patients with rheumatoid arthritis: A retrospective analysis using electronic medical record data.

International journal of clinical rheumatology·2018
Same journal

Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis.

International journal of clinical rheumatology·2016
Same journal

Improving treatment adherence in patients with rheumatoid arthritis: what are the options?

International journal of clinical rheumatology·2016
Same journal

Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions.

International journal of clinical rheumatology·2016
Same journal

Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

International journal of clinical rheumatology·2015
See all related articles

Related Experiment Video

Updated: May 10, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Biologic agents in systemic vasculitis.

Charles F Henderson1, Philip Seo

  • 15501 Hopkins Bayview Circle, JHAAC, Room 1B.1A, Johns Hopkins University Division of Rheumatology, MD 21224, USA.

International Journal of Clinical Rheumatology
|June 21, 2013
PubMed
Summary
This summary is machine-generated.

Biologic agents offer new hope for systemic necrotizing vasculitis, with anti-B-cell therapies like rituximab showing promise. While anti-TNF agents have mixed results, targeted treatments aim for better efficacy and fewer side effects.

Keywords:
ANCATNFantineutrophil cytoplasmic autoantibodiesbiologic therapiesimmunosuppressionrituximabvasculitis

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Related Experiment Videos

Last Updated: May 10, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Standard vasculitis treatments have side effects and limited efficacy.
  • Need for safer, more effective therapies drives research into biologic agents.

Purpose of the Study:

  • To review advances in biologic therapies for systemic necrotizing vasculitis.
  • To evaluate the efficacy and safety of targeted treatments.

Main Methods:

  • Review of clinical trials and literature on biologic agents.
  • Analysis of anti-TNF and anti-B-cell therapies in various vasculitides.

Main Results:

  • Anti-TNF therapy shows promise for Takayasu's arteritis but has mixed results in other conditions.
  • Anti-B-cell therapy, particularly rituximab, demonstrates efficacy in Wegener's granulomatosis and microscopic polyangiitis.
  • Concerns exist regarding the long-term safety of these biologic agents.

Conclusions:

  • Biologic agents represent a significant advance in vasculitis management.
  • Anti-B-cell therapy is a promising strategy, but long-term safety requires further investigation.
  • Future research focuses on developing targeted therapies with improved outcomes and safety profiles.